Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

6237 items
4:30 PM, Oct 19, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 11 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q CompanyDatePre/post mkt3Q18 EPS est3Q17 EPSExpected chgBiogen Inc. (NASDAQ:BIIB)10/23Pre$6.78$6.317%Illumina Inc. (NASDAQ:ILMN)10/23Post$1.26$1.1114%Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)10/24Pre$1.74$1.4421%Anika Therapeutics Inc. (NASDAQ:ANIK)10/24Post$0.31$0.46-33%Vertex Pharmaceuticals...
4:23 PM, Oct 19, 2018  |  BioCentury | Finance

CuraSen’s SPARK

After debuting with a $54.5 million series A round, CuraSen Therapeutics Inc. hopes to generate clinical proof-of-concept data for at least two neurodegenerative disease programs in the next three years. New Leaf Venture Partners led the...
1:46 PM, Oct 19, 2018  |  BioCentury | Finance

Taiho ups its stakes

After bumping up its evergreen fund from $50 million to $300 million, Taiho Ventures LLC plans to increase its stakes in its portfolio companies. The strategic venture arm of Taiho Pharmaceutical Co. Ltd. launched in 2016...
11:41 AM, Oct 19, 2018  |  BioCentury | Finance

Warp Drive’s winding road to Revolution

After winding through nearly seven years of shifting strategies and a delayed entry into the clinic, Warp Drive Bio Inc. has opted for a takeout by fellow Third Rock Ventures portfolio company Revolution Medicines Inc....
2:45 PM, Oct 12, 2018  |  BioCentury | Finance

Versant seizes the RNA moment

As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics. Versant co-led Gotham’s $54 million series A...
1:57 PM, Oct 12, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least three profitable biotechs and pharmas are slated to report earnings this week. (A) Before U.S. markets open; during trading hours in Europe CompanyDatePre/post mkt3Q18 EPS est3Q17 EPSExpected chgJohnson & Johnson (NYSE:JNJ)10/16Pre$2.03$1.907%Roche (SIX:ROG;...
1:27 PM, Oct 12, 2018  |  BioCentury | Finance

Spinning out Sitryx

With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the first start-up to emerge from the Immunology Network at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The round, which closed on...
8:03 AM, Oct 12, 2018  |  BioCentury | Finance

A Glympse at drug response

Investors poured $22 million into Glympse Bio Inc.’s series A round after the company established plans to apply its non-invasive sensors to both diagnostics and drug response monitoring. Polaris Partners and Arch Venture Partners co-led...
6:19 PM, Oct 05, 2018  |  BioCentury | Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs have pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
6:14 PM, Oct 05, 2018  |  BioCentury | Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market for investors through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18...

Pages